Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.36 |
| ▸ | LCAT | P04180 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | ME2 | P23368 | 1/20 | 0.34 |
| ▸ | ME1 | P48163 | 1/20 | 0.34 |
| ▸ | ME3 | Q16798 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31073333 | 0.80 | DGAT1 (0.35) | HRH3AOC3LCATCHIA | |
| SCHEMBL10331958 | 0.77 | LCAT (0.47) | HRH3RETAOC3LCATCYP11B1 | |
| SCHEMBL14852686 | 0.77 | HRH3 (0.73) | HRH3 | |
| SCHEMBL31073137 | 0.77 | GCK (0.37) | AOC3CYP11B1CYP11B2GPR119KDM4E | |
| SCHEMBL15952786 | 0.75 | HRH3 (0.45) | HRH3 | |
| SCHEMBL16210960 | 0.74 | GPR119 (0.43) | GPR119 | |
| Hydrochloric Acid SCHEMBL5009905 | 0.73 | JAK2 (0.43) | HRH3RETAOC3KDM4EABL1 | |
| SCHEMBL23355718 | 0.72 | RORC (0.36) | HRH3KDM4E | |
| SCHEMBL1535653 | 0.72 | TSHR (0.36) | LMNA | |
| SCHEMBL8196788 | 0.72 | JAK2 (0.42) | HRH3TRPV1RETAOC3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763978-B1 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | NOVARTIS AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| EP-2763978-B1 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | NOVARTIS AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-9216182-B2 | Carbamate/urea derivatives containing piperidin and piperazin rings as H3 receptor inhibitors | NOVARTIS AG (CH) | 2015-12-22 | — | — | US | disclosed |
| US-9216182-B2 | Carbamate/urea derivatives containing piperidin and piperazin rings as H3 receptor inhibitors | NOVARTIS AG (CH) | 2015-12-22 | — | — | US | disclosed |
| US-9216182-B2 | Carbamate/urea derivatives containing piperidin and piperazin rings as H3 receptor inhibitors | NOVARTIS AG (CH) | 2015-12-22 | — | — | US | disclosed |
| US-20140235609-A1 | CARBAMATE/UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | SHANGHAI CHEMPARTNER CO., LTD (CN) | 2014-08-21 | — | — | US | disclosed |
| US-20140235609-A1 | CARBAMATE/UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | SHANGHAI CHEMPARTNER CO., LTD (CN) | 2014-08-21 | — | — | US | disclosed |
| US-20140235609-A1 | CARBAMATE/UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | SHANGHAI CHEMPARTNER CO., LTD (CN) | 2014-08-21 | — | — | US | disclosed |
| EP-2763978-A1 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | Novartis AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013050987-A9 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | NOVARTIS AG (CH) | 2013-07-25 | — | — | WO | disclosed |
| WO-2013050987-A9 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | NOVARTIS AG (CH) | 2013-07-25 | — | — | WO | disclosed |
| WO-2013050987-A1 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | NOVARTIS AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013050987-A1 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | NOVARTIS AG (CH) | 2013-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235609-A1 | CARBAMATE/UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | HRH3, HRH4, H1-5 | HRH3 1/4885TRPV1 388/4885RET 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.